Pronizor 30 mg Delayed release capsules
PDF Leaflet Revision Date: 10 July 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Short-term treatment of active duodenal ulcers, reflux oesophagitis, and gastric ulcers.
Dosage (summary)
One 30 mg capsule once daily for up to 8 weeks; adjust to 15 mg if adequate.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation.
Key Drug Interactions
- Atazanavir
- Nelfinavir
- Digoxin
- Warfarin
Contraindications
- Hypersensitivity to lansoprazole
- Pregnancy
- Lactation
- Liver impairment
Common side effects
- Diarrhoea
- Nausea
- Vomiting
- Headache
- Fatigue
Counselling Points
- Take before meals
- Monitor magnesium levels
- Avoid alcohol and CNS depressants
Serious warnings
- Acute interstitial nephritis
- Risk of Clostridium difficile infection
- Bone fracture risk
Important Disclaimer
The Pronizor 30 mg Delayed release capsules professional information leaflet below is the property of Macleods Pharmaceuticals Sa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
